Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
1.
J Pediatr ; 225: 263-268, 2020 10.
Article in English | MEDLINE | ID: mdl-32511960

ABSTRACT

We demonstrated the sustained impact over a 5-year period of a clinical examination-based approach to identification of early-onset sepsis in late preterm and term neonates at our hospital. To date, more than 20 000 neonates have been safely managed using this approach, resulting in a 63% reduction in antibiotic use.


Subject(s)
Neonatal Screening/methods , Neonatal Sepsis/diagnosis , Anti-Bacterial Agents/therapeutic use , Cohort Studies , Female , Humans , Infant, Newborn , Infant, Premature , Interrupted Time Series Analysis , Neonatal Sepsis/drug therapy , Pregnancy , Quality Improvement
2.
Acta Paediatr ; 107(8): 1350-1356, 2018 08.
Article in English | MEDLINE | ID: mdl-29532503

ABSTRACT

AIM: To identify neonates at risk of haemolytic hyperbilirubinaemia through near-concurrent measurements of total serum/plasma bilirubin (TB) or transcutaneous bilirubin (TcB) and end-tidal breath carbon monoxide (CO), corrected for ambient CO (ETCOc), an index of bilirubin production and haemolysis. METHODS: Paired TB/TcB (mg/dL) and ETCOc (ppm) measurements were obtained in newborns (n = 283) at 20 to <60 hours of age in five nurseries. TB/TcB values were assigned TB/TcB percentile risk values using the Bhutani hour-specific nomogram. In infants having two serial TB/TcB measurements (n = 76), TB rate of rise (ROR, mg/dL/h) was calculated. RESULTS: For the entire cohort (n = 283), 67.1% and 32.9% had TB/TcB<75th and ≥75th percentile, respectively. TB/TcB (5.79 ± 1.84 vs 9.14 ± 2.25 mg/dL) and ETCOc (1.61 ± 0.45 vs 2.02 ± 1.35 ppm, p = 0.0002) were different between the groups. About 36.6% of infants with TB/TcB ≥75th percentile had ETCOc ≥ 2.0 ppm. In the subcohort of infants with serial TB/TcB measurements (n = 76), 44.7% and 55.3% had TB/TcB<75th and ≥75th percentile, respectively. TB/TcB (5.28 ± 1.97 vs 9.53 ± 2.78 mg/dL), ETCOc (1.72 ± 0.48 vs 2.38 ± 1.89 ppm, p = 0.05) and TB ROR (0.011 ± 0.440 vs 0.172 ± 0.471 mg/dL/h) were different between the groups. CONCLUSION: The combined use of TB/TcB percentile risk assessments and ETCOc measurements can identify infants with haemolytic hyperbilirubinaemia. The addition of TB ROR can identify those infants with elimination disorders.


Subject(s)
Bilirubin/blood , Carbon Monoxide/analysis , Hyperbilirubinemia, Neonatal/diagnosis , Hyperbilirubinemia, Neonatal/therapy , Neonatal Screening/methods , Phototherapy/methods , Analysis of Variance , Cohort Studies , Female , Gestational Age , Hemolysis/physiology , Humans , Infant, Newborn , Male , Nurseries, Infant , Predictive Value of Tests , Prospective Studies , Risk Assessment , Tidal Volume , Treatment Outcome
4.
Acta Paediatr ; 105(5): e189-94, 2016 May.
Article in English | MEDLINE | ID: mdl-26802319

ABSTRACT

AIM: Relative contributions of increased production [by end-tidal carbon monoxide concentrations (ETCOc)] and decreased elimination of bilirubin to predischarge hour-specific total bilirubin (TB) levels were assessed in healthy late-preterm and term newborns. Secondly, we report predischarge ETCOc ranges to guide clinical management of hyperbilirubinemia. METHODS: TB and ETCOc (≤3 timepoints) determinations of newborns aged between six hours and <6 days (n = 79) were stratified by postnatal age epochs. Hyperbilirubinemia risk was assessed by plotting TB values as a function of ETCOc. RESULTS: Stratifications of ETCOc (in ppm, mean, median and interquartile ranges) by postnatal age epochs (0-24, 24-48 and 48-72) were as follows: 2.0, 1.9, 1.8-2.2 (n = 11); 1.6, 1.5, 1.1-2.0 (n = 58); and 2.0, 1.8, 1.6-2.3 (n = 9), respectively. Infants with ETCOc ≥ 2.5 were at high risk, between 1.5 and 2.5 at moderate risk and ≤1.5 were at low risk. Risk due to haemolysis alone was not independent (p < 0.01). For infants with TB >75th percentile (n = 31), 23% had ETCO ≤1.5, and 77% had ETCOc > 1.5 (p < 0.00003). CONCLUSION: Near-simultaneous ETCOc and TB measurements in infants with TB >75th percentile accurately identify haemolytic hyperbilirubinemia.


Subject(s)
Hemolysis , Hyperbilirubinemia, Neonatal/diagnosis , Algorithms , Bilirubin/blood , Biomarkers/metabolism , Carbon Monoxide/metabolism , Clinical Decision-Making , Decision Support Techniques , Female , Humans , Hyperbilirubinemia, Neonatal/etiology , Hyperbilirubinemia, Neonatal/metabolism , Infant, Newborn , Male , Patient Discharge , Point-of-Care Testing , Reference Values
5.
Pediatr Dermatol ; 31(1): e36-7, 2014.
Article in English | MEDLINE | ID: mdl-23679208

ABSTRACT

Salivary gland choristoma (heterotopic salivary gland tissue) is a rare condition typically seen in the newborn period. This developmental heterotopia is generally nonprogressive, with little risk of malignant transformation. We present the second known reported case of a salivary gland choristoma located on the anterior chest wall. Knowledge of this rare entity will allow for accurate diagnosis and management of this benign anatomic variant.


Subject(s)
Choristoma/pathology , Salivary Glands , Skin Diseases/pathology , Biopsy , Female , Humans , Infant, Newborn , Thoracic Wall
6.
J Neurosurg Pediatr ; 31(5): 484-487, 2023 05 01.
Article in English | MEDLINE | ID: mdl-36840732

ABSTRACT

OBJECTIVE: The purpose of this study was to find areas of agreement among pediatric neurosurgeons with respect to the clinical management of asymptomatic newborns with a variety of lumbosacral skin findings. METHODS: An electronic survey containing 18 clinical images and brief vignettes was sent to pediatric neurosurgeons within the American Academy of Pediatrics Section of Neurological Surgery (AAP SONS). In total, 38% (n = 21) of AAP SONS members submitted complete responses to the survey. Respondents were asked if they would advise routine care, watchful waiting, imaging, or subspecialty consultation for each clinical case. Responses were categorized into two groups: 1) watchful waiting and/or routine care, or 2) imaging and/or subspecialty consultation. Consensus was categorized as good (> 90% of responses in the same group), modest (70%-90%), and poor (< 70%). Demographic information, local factors impacting management, and experiences with local referral patterns were also collected. RESULTS: Among the pediatric neurosurgeons within the AAP SONS network, the authors found high levels (> 90%) of agreement that subcutaneous lipomas, faun tail nevi, large skin tags, and deep/atypical lumbosacral dimples in asymptomatic newborns should prompt an imaging study. Similarly, the authors found high agreement that simple coccygeal dimples do not need imaging. The management of some types of lumbosacral vascular marks and gluteal crease deviations had poor agreement (< 70%). When imaging was recommended, there was preference for spinal MRI in most cases (67%). CONCLUSIONS: Pediatric neurosurgeons generally agree that imaging of the spine is indicated for asymptomatic newborns with subcutaneous lipomas, faun tail nevi, large skin tags, or deep/atypical lumbar dimples (deep or atypical appearing). They also agree that imaging is unnecessary for infants with simple coccygeal dimples. There was a notable lack of consensus on the appropriate management of certain gluteal cleft deviations and cutaneous vascular marks.


Subject(s)
Lipoma , Neurosurgery , Infant , Humans , Infant, Newborn , Child , Spine , Neurosurgical Procedures , Magnetic Resonance Imaging
8.
Hosp Pediatr ; 9(4): 227-233, 2019 04.
Article in English | MEDLINE | ID: mdl-30833294

ABSTRACT

BACKGROUND: Antibiotic use in well-appearing late preterm and term chorioamnionitis-exposed (CE) infants was reduced by 88% after the adoption of a care approach that was focused on clinical monitoring in the intensive care nursery to determine the need for antibiotics. However, this approach continued to separate mothers and infants. We aimed to reduce maternal-infant separation while continuing to use a clinical examination-based approach to identify early-onset sepsis (EOS) in CE infants. METHODS: Within a quality improvement framework, well-appearing CE infants ≥35 weeks' gestation were monitored clinically while in couplet care in the postpartum unit without laboratory testing or empirical antibiotics. Clinical monitoring included physician examination at birth and nurse examinations every 30 minutes for 2 hours and then every 4 hours until 24 hours of life. Infants who developed clinical signs of illness were further evaluated and/or treated with antibiotics. Antibiotic use, laboratory testing, and clinical outcomes were collected. RESULTS: Among 319 initially well-appearing CE infants, 15 (4.7%) received antibiotics, 23 (7.2%) underwent laboratory testing, and 295 (92.5%) remained with their mothers in couplet care throughout the birth hospitalization. One infant had group B Streptococcus EOS identified and treated at 24 hours of age based on new-onset tachypnea and had an uncomplicated course. CONCLUSIONS: Management of well-appearing CE infants by using a clinical examination-based approach during couplet care in the postpartum unit maintained low rates of laboratory testing and antibiotic use and markedly reduced mother-infant separation without adverse events. A framework for repeated clinical assessments is an essential component of identifying infants with EOS.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Chorioamnionitis/drug therapy , Infant Care/methods , Infant, Premature , Postpartum Period , Chorioamnionitis/therapy , Disease Management , Female , Humans , Infant, Newborn , Intensive Care Units, Neonatal , Male , Mother-Child Relations , Pregnancy
9.
Pediatrics ; 141(4)2018 04.
Article in English | MEDLINE | ID: mdl-29599112

ABSTRACT

BACKGROUND: The risk of early-onset sepsis is low in well-appearing late-preterm and term infants even in the setting of chorioamnionitis. The empirical antibiotic strategies for chorioamnionitis-exposed infants that are recommended by national guidelines result in antibiotic exposure for numerous well-appearing, uninfected infants. We aimed to reduce unnecessary antibiotic use in chorioamnionitis-exposed infants through the implementation of a treatment approach that focused on clinical presentation to determine the need for antibiotics. METHODS: Within a quality-improvement framework, a new treatment approach was implemented in March 2015. Well-appearing late-preterm and term infants who were exposed to chorioamnionitis were clinically monitored for at least 24 hours in a level II nursery; those who remained well appearing received no laboratory testing or antibiotics and were transferred to the level I nursery or discharged from the hospital. Newborns who became symptomatic were further evaluated and/or treated with antibiotics. Antibiotic use, laboratory testing, culture results, and clinical outcomes were collected. RESULTS: Among 277 well-appearing, chorioamnionitis-exposed infants, 32 (11.6%) received antibiotics during the first 15 months of the quality-improvement initiative. No cases of culture result-positive early-onset sepsis occurred. No infant required intubation or inotropic support. Only 48 of 277 (17%) patients had sepsis laboratory testing. The implementation of the new approach was associated with a 55% reduction (95% confidence interval 40%-65%) in antibiotic exposure across all infants ≥34 weeks' gestation born at our hospital. CONCLUSIONS: A management approach using clinical presentation to determine the need for antibiotics in chorioamnionitis-exposed infants was successful in reducing antibiotic exposure and was not associated with any clinically relevant delays in care or adverse outcomes.


Subject(s)
Chorioamnionitis/diagnosis , Monitoring, Physiologic/standards , Nurseries, Hospital/standards , Prenatal Exposure Delayed Effects/diagnosis , Quality Improvement/standards , Anti-Bacterial Agents/therapeutic use , Chorioamnionitis/blood , Chorioamnionitis/drug therapy , Female , Humans , Infant, Newborn , Monitoring, Physiologic/methods , Outcome Assessment, Health Care/methods , Outcome Assessment, Health Care/standards , Pregnancy , Prenatal Exposure Delayed Effects/blood , Prenatal Exposure Delayed Effects/drug therapy
10.
Hosp Pediatr ; 11(9): e192-e194, 2021 09.
Article in English | MEDLINE | ID: mdl-34362760
SELECTION OF CITATIONS
SEARCH DETAIL